Activase May Be Reclassified With Separate DRG Under Medicare Part A
Executive Summary
The Centers for Medicare & Medicaid Services is considering the creation of a separate diagnosis-related group for the use of drugs like Genentech's Activase to treat ischemic strokes under Medicare Part A
You may also be interested in...
Guilford Expects Medicare Payment Boost For Gliadel Starting Oct. 1
A new Medicare hospital payment category covering Guilford's Gliadel Wafer is expected to raise the reimbursement rate for the chemotherapy implant effective Oct. 1
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials